You are here: Home / GW Innovations / Technologies Available

Technologies Available

Browse by Category

Recent Technologies

System for Predicting Cloud Service Level Agreement Performance & Trustworthiness

019-040-maeser – Researchers at The George Washington University are developing a system and method for applying statistical and machine learning models to calculate and rank cloud service provider (CSP) trustworthiness levels and predict cloud computing service performance and availability compliance against industry standards based cloud service level agreements (SLAs). Considering the rate of adoption... Read More

Aluminum Coated Silicon Nanoparticles for Li-ion Battery Anodes (inexpensive and air/water stable)

017-028-wagner – Researchers at The George Washington University are developing an innovative material for use in Li-ion battery anodes. The market for Li-ion battery ANODE materials is about $1 billion per year. The market is expected to grow rapidly in the following decades because of electric vehicles. Current Li-ion batteries use mostly graphite anodes. Silicon (Si) is an attractive active material in... Read More

Production of Li-Ion Battery-Grade Graphite (environmentally friendly and inexpensive)

018-004-wagner – Researchers at The George Washington University are developing an innovative method to make high purity crystalline flake graphite from low-cost biomass. The novel Graphite technology invented at GW will slash cost of Li-Ion battery grade graphite (99.5% purity) by more than 80% (from about $20,000/ton to $2,500/ton).  Considering the “STRATEGIC” nature of this technology and the high demand... Read More

Network Design for Chiplet-based Manycore Architecture

020-056-louri-hao – Researchers at The George Washington University are developing a flexible interconnection network design, called Adapt-Net, for chiplet-based manycore architectures. The goal of Adapt-Net is to support the concurrent communication of diverse applications running at the same time, improving the energy-efficiency and performance of the manycore architecture. Today’s manycore architectures are... Read More

Wild-type (WT) and FSM-resistant, glpT mutant S. schleiferi isolates were treated with MEPicides and the minimal inhibitory concentrations (MIC) determined from overnight growth.

Antibiotic for Veterinary Staphylococcal Infections

018-033-dowd – New bacteriostatic compounds treat Staphylococcal strains that infect bovine, cat, and dog populations. Staphylococcal infections affect an estimated 20% of bovine populations in the dairy industry, and are the single largest indication for antibiotic use on dairy farms. Staphylococcal infections lead to a cost of greater than $1 billion per year to U.S. farms. Isoprenoids are an ancient,... Read More

Treatment of U87 Glioblastoma cells with Plasma Discharge Tube at different time durations (1, 2 & 3 Minutes)

Non-Invasive Plasma Discharge Tube Device for Treating Brain Tumors

019-062-keidar – Treating brain tumors, like glioblastoma, is challenging. Current glioblastoma drugs, Rapamycin and Temozolomide (TMZ), generally only extend life for a matter of months, are not very effective in treating recurring tumors, and have significant clinical toxicity. A novel Plasma Discharge Tube (PDT) device has the potential to be more effective and less toxic. PDT may be used alone or may be... Read More

HDACi potency and HDAC6 selectivity index (SI)

Highly Potent and Selective HDAC6 Inhibitor for Cancer Treatment

020-031-villagra – GW and UIC researchers developed a highly potent Histone Deacetylase (HDAC) inhibitor. HDACs can modulate a multitude of cellular processes and are a part of the regulation of cellular pathways involved in antitumor immune responses. Selective inhibition of HDAC6 slows tumor growth in various cancer models. Currently, many prominent selective HDAC6 inhibitors (HDAC6i) are limited to... Read More

In mice, M1+HDAC6i shows a significant decrease in melanoma tumor size compared to Vehicle or untreated M1.

HDAC6i-Activated Macrophage Cell Therapy

019-057-villagra – The tumor microenvironment (TME) plays a key role in tumor growth and survival. Often the immunosuppressive nature of the TME prevents success of treatments including immune checkpoint blockade (ICB), radiation therapy (RT), and chemotherapy. Macrophages in the TME contribute to its immunosuppressive or immunostimulatory character. M2 macrophages secrete anti-inflammatory cytokines, such as... Read More

Illustration of micro-wells transforming into micro-grooves over time at 37°C.

4D-Printed Programmable Culture Substrate for Controlling Neural Stem Cell Growth

020-006-zhang – Neural stem cells (NSCs) exhibit great promise for treating neurodegenerative diseases and injuries. Treatments will rely on efficient proliferation and differentiation of NSCs into neurons with therapeutic characteristics. Static 2D and 3D microenvironment culture substrates fail to cater to the dynamic cell needs, resulting in sub-optimal, inefficient and uncontrolled differentiation of... Read More

Cisplatin resistant ovarian cancer tumor growth is slowed when treated with DHS. The combination of DHS and Cisplatin proves even more effective, highlighting the re-sensitization of the cancer cells to Cisplatin.

And-1 Inhibition by DHS for Cancer Treatment

017-039-zhu – GW researchers developed DHS (4,4’-trans-dihydroxystilbene) as a new cytotoxic anticancer drug for use alone or in combination with other chemotherapies. Drug toxicity and drug resistance limit the ability of many cytotoxic cancer drugs to effectively treat cancer, a problem which is overcome by DHS. The cancer killing efficacy of DHS is 10-times better than its parent compound, resveratrol,... Read More

More Results »